Inclusion Criteria:

          -  Compliance with all study procedures and visits to the clinical research site

          -  Locally advanced or metastatic disease that is not amenable to definitive therapy

          -  Histologically confirmed diagnosis of a solid tumor which expresses c-Met

          -  Must have progressed or have been intolerant to all available therapies known to
             confer clinical benefit appropriate for the patient's tumor type

          -  Measurable baseline disease as defined by RECIST Version 1.1

          -  ECOG Performance Status 0-1

          -  Body weight within 40 and 150 kg

          -  Clinical laboratory values with the limits as defined by the protocol

          -  Not pregnant or breast feeding

          -  Males and women of child-bearing potential must agree to use an effective method of
             contraception

        Exclusion Criteria:

          -  Any disease or condition that may be considered to pose an increased risk from study
             treatment or the ability of the patient to participate and comply with study
             procedures

          -  Treatment with anti-cancer therapy (including cytotoxic chemotherapy, major surgery,
             radiation, biologic and investigational agents) within 21 days before first dose of
             study treatment

          -  Brain metastases that has not stabilized for at least 28 days after therapy and who
             have discontinued steroids for <2 weeks

          -  Unresolved adverse events >= Grade 2 from prior anticancer therapies

          -  Acute myocardial infarction, cerebral ischemic infarct, or other arterial thrombosis
             within 6 months of screening for this study.

          -  Uncontrolled hypertension, unstable angina, or NYHA Class III/IV heart failure

          -  Untreated or uncontrolled bacterial, viral or fungal infection

          -  HIV infection or active infection with hepatitis B or C

          -  Prior treatment with a c-Met targeted agent

          -  Prior hypersensitivity reaction to treatment with another monoclonal antibody

          -  QTcF >=470 ms

          -  Administration of a live, attenuated vaccine within 28 days before the first dose of
             study treatment